BEAM THERAPEUTICS DL-,01

Beam Therapeutics reported comprehensive advances across its base‑editing pipeline, including an expected BLA submission for Risto‑cel in sickle cell disease by the end of 2026 (possibly early 2027) and ongoing recruitment of the approval‑relevant cohort for BEAM‑302 (alpha‑1‑antitrypsin deficiency). An active IND is in place for BEAM‑304 (PKU) and patient screening is planned to start by the end of 2026; BEAM‑301 (GSD1a) could yield first human data in 2026. Management emphasized the platform‑based development approach, agreed regulatory collaboration with the FDA, and funding intended to support operations through mid‑2029. » Altro su de.investing.com

Beam Therapeutics presented clinical progress of its base‑editing platform at the Wells Fargo Healthcare Conference, notably with BEAM‑302 for alpha‑1 antitrypsin deficiency, which produced AAT levels above the protective threshold in all patients and durability beyond 18 months. Safety events were mostly limited to reversible liver enzyme elevations; there were no signs of liver injury or hospitalization. The company is advancing programs for sickle cell disease (Risto‑Cel, BLA plan by year‑end), PKU (BEAM‑304 IND cleared) and GSD1A, and expects multiple milestones in the next 12–18 months. A $500 million financing facility from Sixth Street is intended to support commercialization of the sickle cell therapy, while competition in the alpha‑1 field is increasing; Beam continues to see a multi‑year lead in base editing. » Altro su de.investing.com

Beam Therapeutics presented updated Phase 1/2 data on BEAM-302 for alpha-1 antitrypsin deficiency at the ERS Congress. At 60 mg, mean circulating AAT levels rose above the protective threshold of 11 µM and mutant Z‑AAT was reduced by 84%, while corrected M‑AAT accounted for about 93% of circulating AAT. The treatment was well tolerated for up to 18 months; 41% of patients experienced mild to moderate infusion-related reactions. Beam selects 60 mg as the target dose, plans an expansion of roughly 50 patients and is pursuing an accelerated approval pathway in the US. » Altro su de.investing.com